Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAR-engineered T-cell therapy is the most promising immunotherapy in the field of cancer therapy and has been shown to eliminate the ability of various tumors, especially for hematopoietic malignancies, to achieve durable and complete remission. However, the efficacy of CAR-T cells against solid tumors has lagged, which may be due to insufficient expansion and persistence of CAR-T cells.
Benefiting from advanced technology and years of experience, Creative Biolabs is gaining even greater success in developing innovative next-generation CAR-T products. We are proud to present a novel CAR construct - IL-8R-modified CAR, that is most likely to exert maximum anti-tumor efficacy in solid tumors.
Introduction of IL-8R-modified CAR
There is evidence that IL-8 promotes tumor progression through multiple mechanisms: enhancing the recruitment of tumor-associated neutrophils or MDSCs, activating epithelial-mesenchymal transition, promoting angiogenesis, and holding enhanced resistance, stemness and metastatic potential. Therefore, IL-8 creates significant barriers to anti-tumor treatment. Inspired by this rationale, we modified the original CAR with interleukin-8 receptors such as CXCR1 and CXCR2. This novel CAR design construct may facilitate tumor-producing IL-8-directed IL-8 receptor-modified CAR-T cells to migrate into tumors and induce enhanced anti-tumor responses in solid tumors.
Fig.1 Schematic representation of IL-8R-modified CAR.
IL-8R-modified CAR Design & Construction Services
Take the IL-8R-modified CD70 CAR as an example. For the regular CAR backbone construction, please refer to our related services: CAR Design & Construction. After the CD70 CAR backbone construct was obtained, the human IL-8 receptor CXCR1 and CXCR2 cDNAs were subcloned downstream of CD70CAR using our integrated DNA technology. If you need EGFP as a control, we can also provide you with the EGFP-modified CD70 CAR construct for your research.
To further assess IL-8R-modified CAR efficacy in vitro and in vivo, we also provide comprehensive downstream services for assessing the biological efficacy of IL-8R-modified CAR-T cells (e.g., cytokine production, tumor killing, and CAR-T cell proliferation). For more details, please click CAR Cell In Vitro Assay Service, CAR-T Preclinical In Vivo Assay.
Fig.2 Example schematic of CD70-specific IL-8R-modified CAR.
IL-8 Availability
As a professional bioreagent supplier in the field of cell therapy, we guide our clients, every step of the way, to accelerate and promote the progress of your CAR-T projects. Therefore, as part of the end-to-end service, we also provide a variety of cytokine kits to accelerate your research. Human IL-8 cytokine protein is certainly available.
For more detailed information, please feel free to contact us or directly sent us an inquiry.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
